KaloBios Bankruptcy Plan, Shkreli Settlement Win Court Approval
KaloBios Pharmaceuticals Inc. won bankruptcy court approval of a reorganization plan that shrinks former CEO Martin Shkreli’s stake to about 14 percent, Bloomberg reported on Wednesday. U.S. Bankruptcy Judge Laurie Silverstein agreed to the plan and the proposal was accepted by all classes entitled to vote and “all parties are receiving more than they would receive in a liquidation,” she said. The drugmaker filed for bankruptcy in December, shortly after he was arrested on fraud charges related to other businesses he was involved in. He denies the allegations. As a result of additional shares being issued, Shkreli’s stake in KaloBios would shrink to about 14 percent from about 47 percent. KaloBios also won approval of several settlements incorporated into the plan, including one with Shkreli. The bankruptcy is In re KaloBios Pharmaceuticals Inc., 15-12628, U.S. Bankruptcy Court, District of Delaware (Delaware).
